Integrin Beta 7 - Pipeline Review, H2 2019
Integrin Beta 7 - Pipeline Review, H2 2019
SUMMARY
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease).
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD) and Human Immunodeficiency Virus (HIV) Infections (AIDS).
The latest report Integrin Beta 7 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease).
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD) and Human Immunodeficiency Virus (HIV) Infections (AIDS).
The latest report Integrin Beta 7 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
C4X Discovery Holdings Plc
Genentech Inc
Morphic Holding Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize Integrin alpha4 and Integrin beta7 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGA4 and ITGB7 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2019: Takeda submits NDA for SC formulation of vedolizumab to treat ulcerative colitis
Aug 01, 2019: Oral Alpha-4-Beta-7 integrin antagonist PN-943 demonstrates sustained dose-related target engagement activity in a multiple ascending dose phase 1 study
Jul 22, 2019: Takeda’s study of subcutaneous vedolizumab meets primary goal
May 22, 2019: Entyvio (vedolizumab) approved in Japan for the treatment of patients with moderately to severely active Crohn's Disease
May 19, 2019: New Exploratory data from VARSITY, the first head-to-head ulcerative colitis biologic study which demonstrated superiority of Vedolizumab to Adalimumab in clinical remission at week 52, presented at 2019 Digestive Disease Week
May 14, 2019: Oral alpha-4-beta-7 integrin antagonist PN-943 demonstrates superior dose-related target engagement activity to PTG-100 in single ascending dose phase 1 study
May 09, 2019: U.S. Food & Drug Administration accepts Takeda's Biologics License Application for a subcutaneous formulation of Vedolizumab (Entyvio) for maintenance therapy in moderately to severely active ulcerative colitis
May 07, 2019: Protagonist Therapeutics to present preclinical data on PN-943 at Digestive Disease Week conference 2019
Apr 01, 2019: European Medicines Agency accepts Takeda's Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn's Disease
Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis
Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head
Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials
Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease
Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
C4X Discovery Holdings Plc
Genentech Inc
Morphic Holding Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize Integrin alpha4 and Integrin beta7 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGA4 and ITGB7 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2019: Takeda submits NDA for SC formulation of vedolizumab to treat ulcerative colitis
Aug 01, 2019: Oral Alpha-4-Beta-7 integrin antagonist PN-943 demonstrates sustained dose-related target engagement activity in a multiple ascending dose phase 1 study
Jul 22, 2019: Takeda’s study of subcutaneous vedolizumab meets primary goal
May 22, 2019: Entyvio (vedolizumab) approved in Japan for the treatment of patients with moderately to severely active Crohn's Disease
May 19, 2019: New Exploratory data from VARSITY, the first head-to-head ulcerative colitis biologic study which demonstrated superiority of Vedolizumab to Adalimumab in clinical remission at week 52, presented at 2019 Digestive Disease Week
May 14, 2019: Oral alpha-4-beta-7 integrin antagonist PN-943 demonstrates superior dose-related target engagement activity to PTG-100 in single ascending dose phase 1 study
May 09, 2019: U.S. Food & Drug Administration accepts Takeda's Biologics License Application for a subcutaneous formulation of Vedolizumab (Entyvio) for maintenance therapy in moderately to severely active ulcerative colitis
May 07, 2019: Protagonist Therapeutics to present preclinical data on PN-943 at Digestive Disease Week conference 2019
Apr 01, 2019: European Medicines Agency accepts Takeda's Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn's Disease
Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis
Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head
Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials
Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease
Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by C4X Discovery Holdings Plc, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Morphic Holding Inc , H2 2019
Pipeline by Protagonist Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by C4X Discovery Holdings Plc, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Morphic Holding Inc , H2 2019
Pipeline by Protagonist Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
C4X Discovery Holdings Plc
Genentech Inc
Morphic Holding Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
C4X Discovery Holdings Plc
Genentech Inc
Morphic Holding Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
